XNASDRTSW
Market cap24mUSD
Jan 15, Last price
0.34USD
1D
16.67%
1Q
96.41%
IPO
-62.37%
Name
Healthcare Capital Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-29m
L-13.64%
CFO
-18m
L-24.80%
Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 36,754 | 33,115 | |||
Unusual Expense (Income) | |||||
NOPBT | (36,754) | (33,115) | |||
NOPBT Margin | |||||
Operating Taxes | 16 | 20 | |||
Tax Rate | |||||
NOPAT | (36,770) | (33,135) | |||
Net income | (29,157) -13.64% | (33,762) 23.80% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 49 | 3,362 | |||
BB yield | -0.37% | -21.16% | |||
| Debt | |||||
Debt current | 1,062 | 669 | |||
Long-term debt | 19,880 | 9,717 | |||
Deferred revenue | |||||
Other long-term liabilities | 3,597 | 5,630 | |||
Net debt | (60,846) | (94,144) | |||
| Cash flow | |||||
Cash from operating activities | (17,958) | (23,879) | |||
CAPEX | (6,401) | (904) | |||
Cash from investing activities | 18,682 | (89,936) | |||
Cash from financing activities | 5,297 | 96,905 | |||
FCF | (44,650) | (38,870) | |||
| Balance | |||||
Cash | 81,788 | 104,530 | |||
Long term investments | |||||
Excess cash | 81,788 | 104,530 | |||
Stockholders' equity | (115,759) | (86,602) | |||
Invested Capital | 217,107 | 203,082 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 69,378 | 63,535 | |||
Price | 0.19 -22.99% | 0.25 -48.91% | |||
Market cap | 13,362 -15.91% | 15,890 -19.90% | |||
EV | (47,484) | (78,254) | |||
EBITDA | (35,680) | (32,136) | |||
EV/EBITDA | 1.33 | 2.44 | |||
Interest | 39 | 1,769 | |||
Interest/NOPBT | |||||